Become a
SuperHealer™
By restoring the body’s capacity for organized tissue regeneration, Eluciderm aims to give people back what injury often takes away.
Eluciderm & The Return
to Generative Healing
Before Birth
Before birth, the body builds tissues through highly coordinated developmental programs. Wnt signaling guides vascularization, polarity, and structural organization, allowing skin and other tissues to form with flexibility, architecture, and functional integrity rather than scar.
Fibrotic Repair Dominates
Following Birth
Following birth, the body favors rapid wound closure, activating early canonical Wnt/β-catenin signaling that drives fibrotic repair. While effective for survival, this process often leaves behind scar tissue that compromises long-term tissue quality and function.
Insight
Eluciderm was founded on the observation that fibrosis and tissue repair may be distinct biological processes. By temporarily suppressing early scar-forming signals, generative modeling programs may become accessible during healing.
Generative Repair Encouraged
Discovery
Eluciderm molecules modulate Poly(ADP-ribose) Polymerase (PARP) enzymes, influencing repair pathways that help determine whether tissue heals through fibrosis or more organized regeneration.
This Restorative Reset™ is designed to guide healing away from fibrosis and toward healthier tissue restoration.
Platform
Eluciderm has developed a platform of small molecules designed for Multi-PARP* Modulation, a multi-dimensional approach to tissue repair that targets fibrosis, inflammation, immune signaling, and regeneration. Applications include wound healing, regenerative medicine, aesthetics, fibrosis, immunology, and oncology.
*Poly(ADP-ribose) polymerase (PARP) enzymes are involved in detecting and repairing DNA damage.
Eluciderm's Targeted PARP Enzymes
PARP-1
Improves angiogenesis; Modulates DNA repair (Anti-Cancer)
PARP-2
Improves immune cell function; Modulates DNA repair and controls cellular growth (Anti-Cancer)
PARP-5
Inhibition dynamically modulates Wnt signaling pathway, decouples fibrotic response, promotes angiogenesis and the regenerative response while controlling cellular growth (Anti-Cancer)
PARP-10
Inhibition affects cell proliferation and stress response differently from PARP-1 and PARP-2
PLATFORM OF SMALL MOLECULES
ELU42
Topical spray-on solution for open wound healing
ELU116
Topical investigational product for scar reduction and collagen enhancement
ELU507
Investigational inhalation product candidate for pulmonary fibrosis
ELU511
Topical investigational product for surgical and invasive procedure wound healing
ELU535
Topical investigational product for elastic cartilage regeneration
ELU569
ELU643
ELU700
NCI candidates for their potential as a treatment of leukemia and malignant melanoma
ELU42
ELU42 is Eluciderm’s lead therapeutic candidate and the first molecule developed from the company’s regenerative repair platform.
Winner
International Symposium for Advanced Wound Care (SAWC)
2024 WHS WoundShark Innovation Award
2026 Industrial R&D Award for Research on ELU42 Mechanism of Action
Skin Regeneration
Anywhere / Anytime
Unlike many wound treatments that have focused on oral, intravenous or injectable routes of administration, our patented lead therapeutic candidate ELU42 is formulated as a topical therapy, allowing treatment to be delivered directly to injured tissue while minimizing systemic exposure.
ELU42 Therapeutic Profile:
Regenerative Repair Signaling
Designed to locally modulate PARP-associated repair signaling, ELU42 has demonstrated clinical evidence of reduced fibrotic scarring while supporting angiogenesis, organized collagen remodeling, and regenerative healing.
Broad Clinical Potential
Direct application to wounds and traumatic injuries may enable use across surgical, hospital, wound care, and emergency settings.
Topical (Spray-On) Point-of-Care Delivery
As a topical therapy, ELU42 is designed for application at the site of injury, enabling early intervention when healing outcomes may be most influenced.
Operational Simplicity
Designed for spray-on administration, ELU42 may be stored under refrigerated or room-temperature conditions and applied without the need for a sterile environment, supporting use across diverse care settings.
Safety
Preclinical studies established a NOAEL (No Observed Adverse Effect Level), and Phase IIA clinical data support continued development as a topical therapeutic.
ELU42 exceeds FDA breakthrough therapy guidance benchmarks in Phase I/IIA Clinical Trial for Diabetic Foot Ulcers
ELU42, Eluciderm’s leading therapeutic candidate, is currently in a Phase I/IIA clinical trial, called the SuperHealer™ Trial, for Wagner 1 and 2 diabetic foot ulcers (DFUs) and represents the company’s most advanced stage of clinical readiness.
ClinicalTrials.gov ID: NCT07396376; IND169928
First 5 Subjects
-
86% Average Wound Surface Area Reduction at 4 Weeks
-
Exceeded FDA Breakthrough Therapy Guidance Benchmark
-
100% of Initial Patients Achieved the 50% Healing Threshold
-
Strong Early Clinical Efficacy Signal
First 10 Subjects
-
100% of Patients Exceeded FDA Breakthrough Therapy Guidance Benchmark
-
78% Average Wound Surface Area Reduction at 4 Weeks
-
Rapid Improvement Compared with Standard of Care
-
Statistically Significant Clinical Outcomes by Week 4
Patent Portfolio
Eluciderm’s patents for ELU42 provide protection through 2038, with pending filings that could extend exclusivity to 2047. Nine additional patents extend Eluciderm’s portfolio, covering more than 300 novel small-molecule analogs, strengthening the company’s long-term competitive moat.
